NeoGenomics is trading 5.4% up now at $19.64 in after-hours trading after Medicare expanded coverage for RaDaR ST to monitor immunotherapy response in patients with late-stage solid tumors.
- This is the test’s third Medicare-covered indication and supports broader commercial adoption.
- Shares gained 7.31% during the August 27 regular session, aided by a strong broader market.
- The company-specific catalyst is materially stronger than general market momentum; coverage may improve access to NeoGenomics’ blood-based cancer-monitoring platform and investor expectations for future test volume.